Scientist I - In Vitro Pharmacology jobs in United States
cer-icon
Apply on Employer Site
company-logo

UCB · 22 hours ago

Scientist I - In Vitro Pharmacology

positionCambridge, Massachusetts, US
timeFull-time
remoteHybrid
seniorityNew Grad, Entry, Mid Level
money$98K/yr - $128K/yr
date0+ years exp

UCB is a global biopharmaceutical company, focusing on neurology and immunology. They are seeking a Scientist I - In Vitro Pharmacology to contribute to drug discovery efforts with an emphasis on muscle biology, designing and deploying in vitro models and assays for therapeutic programs.

BiotechnologyHealth CarePharmaceutical
check
H1B Sponsor Likelynote

Responsibilities

Assay Development: Design, characterize and validate bespoke assays to support muscle therapeutic programs
Assay Execution: Conduct cell-based functional assays to characterize compounds or validate new targets
Muscle Biology: Perform in vitro assays to enhance understanding of neuromuscular disease biology
Team Collaboration: Collaborate with cross-functional teams to integrate translational biology insights into therapeutic programs or new target proposals
Data Management: Document, analyze, and present data to internal teams

Qualification

Skeletal muscle biologyVitro pharmacologyCell biologyMolecular biologyLab automationTraining junior researchersData managementCommunicationTeam collaboration

Required

Either an MS with >4 years of industry experience OR a PhD with 0-2 years relevant experience
Skeletal muscle biology expertise
Experience and working knowledge of in vitro pharmacology, cell biology, molecular biology, and lab automation
Excellent communication skills with the proven ability to build collaborative relationships and work effectively as a member of a multidisciplinary team
Works under general direction and may consult management to obtain information to build consensus and project direction. Has thorough knowledge and understanding of concepts and subject matter expertise

Preferred

Experience with culturing a broad variety of mammalian cells; proficiency with maintenance and differentiation of iPSCs and primary cell lines
Experience training junior researchers
Experience with in vivo disease models and ex vivo pharmacology

Company

UCB

twittertwittertwitter
Glassdoor3.9
company-logo
At UCB, we believe everyone deserves to live the best life they can - as free as possible from the challenges and uncertainty of disease.
dateFounded in 1928
location
Brussels, Brussels Hoofdstedelijk Gewest, BEL
people-size5001-10000 employees
web-link
http://www.ucb.com

H1B Sponsorship

UCB has a track record of offering H1B sponsorships. Please note that this does not guarantee sponsorship for this specific role. Below presents additional info for your reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (5)
2024 (7)
2023 (3)
2022 (4)
2021 (4)
2020 (1)

Funding

Current Stage
Public Company
Total Funding
$201.75M
Key Investors
Financière de Tubize SAPaul Capital
2022-05-23Post Ipo Equity· $100.96M
2015-05-13Post Ipo Equity· $0.79M
2009-12-22Post Ipo Equity· $100M

Leadership Team

leader-logo
Jean-Christophe Tellier
CEO
linkedin
leader-logo
Stefanos Grammatikos
Senior Vice President - Head of CMC Development Sciences
linkedin

Recent News

PharmiWeb
UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder
2025-12-10
PR Newswire
UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduced countable motor seizure frequency in CDKL5 deficiency disorder
2025-12-08
PR Newswire
UCB shares leading scientific research and advances at American Epilepsy Society Annual Meeting
2025-12-05
Company data provided by crunchbase